Skip to main content

Table 1 Demographic and disease characteristics of psoriasis patients with self-reported PsA in the PSOLAR registry: Overall population

From: Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics

 Ustekinumab (N = 628)TNF inhibitorsa (N = 1413)Infliximab (N = 258)Etanercept (N = 481)Adalimumab (N = 674)Non-biologic /MTXb (N = 98)Non-biologic /non-MTXc (N = 208)Alld (N = 2401)
Age, years
 Mean ± SD49.7 ± 12.650.4 ± 12.549.5 ± 12.651.1 ± 13.050.4 ± 12.055.6 ± 12.353.4 ± 14.350.8 ± 12.8
Sex
 Men352 (56.1)757 (53.6)138 (53.5)259 (53.8)360 (53.4)34 (34.7)99 (47.6)1272 (53.0)
Race
 White527 (83.9)1157 (81.9)223 (86.4)392 (81.5)542 (80.4)80 (81.6)190 (91.3)2000 (83.3)
Body mass index (BMI) (kg/m2)
 N6171372245471656932032339
 Mean ± SD32.1 ± 7.031.7 ± 7.432.9 ± 8.431.1 ± 7.331.7 ± 7.130.8 ± 7.330.6 ± 6.931.7 ± 7.2
 Obesity class
  N6171372245471656932032339
 Underweight-normal (BMI < 18.5–24.9)80 (13.0)209 (15.2)29 (11.8)81 (17.2)99 (15.1)24 (25.8)41 (20.2)359 (15.3)
 Overweight-obesity class I (25.0–34.9)353 (57.2)779 (56.8)136 (55.5)268 (56.9)375 (57.2)43 (46.2)110 (54.2)1315 (56.2)
 Obesity class II-III (35.0- ≥40)184 (29.8)384 (28.0)80 (32.7)122 (25.9)182 (27.7)26 (28.0)52 (25.6)665 (28.4)
Psoriasis disease characteristics
 Duration of psoriasis, years
  N6271400256477667972082385
  Mean ± SD20.8 ± 13.019.0 ± 13.420.1 ± 13.818.0 ± 13.619.3 ± 13.217.4 ± 13.517.5 ± 15.419.3 ± 13.6
 BSA involvement (%)
  N6161383247472664962052353
  Median6.04.04.03.84.06.08.05.0
 Baseline PGA score
  N6181386249474663962052359
  Mean ± SD2.3 ± 1.21.9 ± 1.21.9 ± 1.21.9 ± 1.22.0 ± 1.32.4 ± 1.12.5 ± 1.12.1 ± 1.2
Medical historye
  PsA628 (100.0)1413 (100.0)258 (100.0)481 (100.0)674 (100.0)98 (100.0)208 (100.0)2401 (100.0)
  Cardiovascular disease272 (43.3)605 (42.8)121 (46.9)214 (44.5)270 (40.1)43 (43.9)100 (48.1)1040 (43.3)
  Psychiatric illness158 (25.2)344 (24.3)69 (26.7)117 (24.3)158 (23.4)21 (21.4)49 (23.6)584 (24.3)
   Anxiety84 (13.4)196 (13.9)40 (15.5)69 (14.3)87 (12.9)10 (10.2)31 (14.9)327 (13.6)
   Depression116 (18.5)236 (16.7)46 (17.8)78 (16.2)112 (16.6)14 (14.3)36 (17.3)413 (17.2)
  Inflammatory bowel disease16 (2.5)37 (2.6)8 (3.1)11 (2.3)18 (2.7)4 (4.1)5 (2.4)64 (2.7)
   Crohn’s disease4 (0.6)9 (0.6)2 (0.8)3 (0.6)4 (0.6)1 (1.0)1 (0.5)16 (0.7)
   Ulcerative colitis3 (0.5)10 (0.7)2 (0.8)2 (0.4)6 (0.9)1 (1.0)1 (0.5)15 (0.6)
   Indeterminate colitis6 (1.0)15 (1.1)4 (1.6)5 (1.0)6 (0.9)2 (2.0)3 (1.4)26 (1.1)
  Pulmonaryf94 (15.0)225 (15.9)40 (15.5)76 (15.8)109 (16.2)21 (21.4)46 (22.1)395 (16.5)
  Hepatic22 (3.5)56 (4.0)14 (5.4)19 (4.0)23 (3.4)2 (2.0)9 (4.3)92 (3.8)
  Skin cancer28 (4.5)88 (6.2)14 (5.4)38 (7.9)36 (5.3)6 (6.1)15 (7.2)144 (6.0)
  Other cancers17 (2.7)48 (3.4)9 (3.5)18 (3.7)21 (3.1)13 (13.3)14 (6.7)95 (4.0)
 Endocrine135 (21.5)315 (22.3)60 (23.3)113 (23.5)142 (21.1)26 (26.5)52 (25.0)539 (22.4)
  Diabetes mellitus type I8 (1.3)23 (1.6)6 (2.3)10 (2.1)7 (1.0)1 (1.0)7 (3.4)39 (1.6)
  Diabetes mellitus type II90 (14.3)181 (12.8)35 (13.6)62 (12.9)84 (12.5)15 (15.3)33 (15.9)325 (13.5)
  Thyroid dysfunction46 (7.3)134 (9.5)25 (9.7)47 (9.8)62 (9.2)13 (13.3)18 (8.7)218 (9.1)
  History of infectionsg167 (26.6)388 (27.5)84 (32.6)137 (28.5)167 (24.8)23 (23.5)43 (20.7)641 (26.7)
 Social activitye
  Alcohol use, N6281413258481674982082401
   Never used130 (20.7)301 (21.3)70 (27.1)91 (18.9)140 (20.8)47 (48.0)55 (26.4)545 (22.7)
   Current user426 (67.8)905 (64.0)161 (62.4)302 (62.8)442 (65.6)35 (35.7)120 (57.7)1521 (63.3)
   Have used and stopped72 (11.5)207 (14.6)27 (10.5)88 (18.3)92 (13.6)16 (16.3)33 (15.9)335 (14.0)
  Smoking, N6281412257481674982082400
   Never smoked256 (40.8)651 (46.1)122 (47.5)220 (45.7)309 (45.8)47 (48.0)85 (40.9)1059 (44.1)
   Current smoker147 (23.4)287 (20.3)61 (23.7)85 (17.7)141 (20.9)24 (24.5)53 (25.5)521 (21.7)
   Prior smoker, stopped225 (35.8)474 (33.6)74 (28.8)176 (36.6)224 (33.2)27 (27.6)70 (33.7)820 (34.2)
  1. Data are n (%) unless otherwise indicated
  2. The biologic user cohort includes patients who are on the cohort defining biologic at entry or start the biologic after entry; previous use or current exposure is allowed for MTX, but not for other systemic immunomodulators
  3. BMI body mass index; BSA body surface area; MTX methotrexate; PGA Physician’s Global Assessment; PsA psoriatic arthritis; PSOLAR Psoriasis Longitudinal Assessment and Registry; SD standard deviation
  4. aTumor necrosis factor (TNF) inhibitors include infliximab, etanercept, and adalimumab
  5. b The non-biologic/MTX cohort includes patients who are on methotrexate at entry or start methotrexate during the registry and haven’t been exposed to other systemic immunomodulators previously or concurrently
  6. cNon-biologic, non-MTX therapies may include, but are not limited to, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, oral corticosteroids, systemic retinoids, psoralen plus ultraviolet (UV), or UVB phototherapy. The non-biologic/non-MTX cohort includes patients who are on other systemic immunomodulators (including cyclosporine, tacrolimus, mycophenolate mofetil, other immunomodulators, and oral corticosteroids) at entry or start other immunomodulators after registry and who haven’t been exposed to MTX previously or concurrently; patients who are on or receive only topical and/or phototherapy at/after registry entry are also in this cohort
  7. dIncludes “Other biologics” group (n = 54); data not shown
  8. eData were collected at baseline (defined as the last non-missing value that is closest and prior to/on the cohort start date)
  9. fIncludes sleep apnea, asthma, chronic obstructive pulmonary disorder, and pneumonitis
  10. gHistory of infections is defined as infections within 3 years of enrollment and required a prescription medication
  11. Obesity class based upon National Heart Lung and Blood Institute Obesity Education Initiative http://www.nhlbi.nih.gov/health/public/heart/obesity/lose_wt/bmi_dis.html